Abstract Library

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#1922 Comparison of Long Terms Outcomes after Resection of Hepatic and /or Peritoneal Metastasis from Neuroendocrine Tumors

Introduction: The complete resection of liver metastasis LM is usually recommended in patients with grade 1-2 NET. The exact benefit of resection of peritoneal metastasis PM is unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Benhaim L

Authors: Benhaim L, Faron M, Gelli M, Boige V, Malka D,

Keywords: Liver metastasis, peritoneal metastasis, surgery,

#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hadoux J

Authors: Hadoux J, Malka D, Berdeloux A, Planchard D, Boige V,

Keywords: Neuroendocrine carcinoma, mismatch repair, microsatellite instability,

#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?

Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Faggiano A,

Keywords: pancreatic neuroendocrine tumor, chemotherapy,

#1452 Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade

Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Borget I,

Keywords: stage IV, pancreatic neuroendocrine tumor, prognosis, survival,